1. Academic Validation
  2. The evolution of small molecule enzyme activators

The evolution of small molecule enzyme activators

  • RSC Med Chem. 2023 Sep 22;14(11):2206-2230. doi: 10.1039/d3md00399j.
Louise F Dow 1 Alfie M Case 1 Megan P Paustian 1 Braeden R Pinkerton 1 Princess Simeon 1 Paul C Trippier 1 2 3
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center Omaha NE 68106 USA paul.trippier@unmc.edu.
  • 2 Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center Omaha NE 68106 USA.
  • 3 UNMC Center for Drug Discovery, University of Nebraska Medical Center Omaha NE 68106 USA.
Abstract

There is a myriad of Enzymes within the body responsible for maintaining homeostasis by providing the means to convert substrates to products as and when required. Physiological Enzymes are tightly controlled by many signaling pathways and their products subsequently control Other pathways. Traditionally, most drug discovery efforts focus on identifying enzyme inhibitors, due to upregulation being prevalent in many diseases and the existence of endogenous substrates that can be modified to afford inhibitor compounds. As enzyme downregulation and reduction of endogenous activators are observed in multiple diseases, the identification of small molecules with the ability to activate Enzymes has recently entered the medicinal chemistry toolbox to afford chemical probes and potential therapeutics as an alternative means to intervene in diseases. In this review we highlight the progress made in the identification and advancement of non-kinase enzyme activators and their potential in treating various disease states.

Figures